1, peptic ulcer: is the most important indication for Hp eradication, eradication of Hp can promote ulcer healing and significantly reduce the recurrence rate and complication rate of ulcers. Hp eradication makes most peptic ulcers no longer a chronic, recurrent disease, but completely curable. 2, gastric mucosa-associated lymphoid tissue lymphoma: is a rare gastric malignancy, about 80% of Hp-positive early stage (lesions limited to the mucosa and submucosa), low-grade gastric MALT lymphoma can obtain a complete response after eradication of Hp, but the efficacy of lesions deeper than the submucosa is reduced. Hp eradication has become the first-line treatment for Hp-positive low-grade gastric MALT lymphoma. 3, Hp-positive chronic gastritis with dyspepsia: or functional anemia associated with Hp eradication can increase hemoglobin levels; Hp eradication can increase platelet counts in more than 50% of patients with idiopathic thrombocytopenic purpura. Randomized controlled studies have confirmed the effectiveness of Hp eradication in lymphocytic gastritis and gastric hyperplastic polyps. Several case reports have reported that Hp eradication is effective for disease treatment. These diseases are clinically rare or lack other effective treatments, and Hp eradication has shown to be effective and is recommended. The correlation between some other extragastric diseases and Hp infection has yet to be confirmed by more studies. 4. Individual request for treatment: Conditions and benefits vary and should be critically evaluated by a physician prior to treatment. Those aged <45 years with no alarm symptoms are supported for Hp eradication; however, those aged ≥45 years or with alarm symptoms are not supported for Hp eradication and need to be examined by endoscopy first. The potential risks of this management strategy, including missed upper gastrointestinal cancers, masking, and adverse drug reactions, should be clearly explained to the patient prior to treatment.